Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Few targets have undergone as dramatic a turnaround as KRAS, one of the most commonly mutated proteins in cancer. For decades KRAS seemed intractable to direct attacks, a teflon target with nowhere for drugs to latch on. But researchers at the University of California, San Francisco identified a scratch in 2013, and everything changed. Ten years on, drug developers have secured FDA approval for two KRAS-G12C-targeted inhibitors, and a dozen or so follow-ons are in the clinic.